Tascenso ODT®.
Tascenso ODT®
(fingolimod)
Tascenso ODT®
Indication
Multiple Sclerosis
Status
- US Launched on February 13, 2023 by Cycle Pharma.
- Exclusive License Agreement with Cycle Pharmaceuticals Ltd. for Commercialization of Tascenso ODT in the USA on March 4th, 2022.
- Final approval for 0.25mg & 0.5mg.